Aucentra Therapeutics is Drug Discovery in Australia that focus on ovarian cancer business. Founded in 2017. They cover business area such as developer, target cancer therapeutic drug, well outcome, patient, a deep pipeline, proprietary target anti-cancer drug, candidate, leukemia, breast cancer, colorectal cancer, glioblastoma, lung cancer, prostate cancer, ovarian cancer, doctor.
2017
( 7 years old in 2024 )
Ovarian Cancer
-
7 Uni Sa Cancer Research Institute
Building Hb North Terrace
Adelaide, South Australia 5000
Australia
Private
developertarget cancer therapeutic drugwell outcomepatienta deep pipelineproprietary target anti-cancer drugcandidateleukemiabreast cancercolorectal cancerglioblastomalung cancerprostate cancerovarian cancerdoctor
* We use standard office opening hours in near Aucentra Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Aucentra Therapeutics is Drug Discovery business from Australia that founded in 2017 (7 years old in 2024), Aucentra Therapeutics business is focusing on Ovarian Cancer.
Aucentra Therapeutics headquarter office and corporate office address is located in 7 Uni Sa Cancer Research Institute Building Hb North Terrace Adelaide, South Australia 5000 Australia.
Aucentra Therapeutics was founded in Australia.
In 2024, Aucentra Therapeutics is currently focus on ovarian cancer sector.
Above is snippet of Google Trends for "ovarian cancer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Aucentra Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
